We hypothesized that next-generation sequencing could reveal actionable genomic alterations (GAs) and potentially expand treatment options for patients with advanced adenoid cystic carcinoma (ACC). Genomic profiling using nextgeneration sequencing was performed on hybridization-captured, adapter ligation libraries derived from 28 relapsed and metastatic formalin-fixed paraffin-embedded ACC. The 3230 exons of 182 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer were fully sequenced using the Illumina HiSeq 2000. All classes of GAs were evaluated. Actionable GAs were defined as those impacting targeted anticancer therapies on the market or in registered clinical trials. A total of 44 GAs were identified in the 28 ACC tumors, with 12 of 28 (42.9%) of tumors harboring at least 1 potentially actionable GA. The most common nonactionable GAs were identified in KD6MA (5 cases; 18%), ARID1A (4 cases; 14%), RUNX1 (2 cases; 7%), and MYC (2 cases; 7%). Actionable GAs included NOTCH1 (3 cases; 11%), MDM2 (2 cases; 7%), PDGFRA (2 cases; 7%), and CDKN2A/B (p16) (2 cases; 7%). Other potentially actionable GAs identified in a single case included: mutations in AKT1, BAP1, EGFR, and PIK3CA, homozygous deletion of FBXW7, and amplifications of CDK4, FGFR1, IGF1R, KDR, KIT, and MCL1. The frequency of GA in ACC is lower than that seen in the more common solid tumors. Comprehensive genomic profiling of ACC can identify actionable GAs in a subset of patients that could influence therapy for these difficult-to-treat progressive neoplasms.
A denoid cystic carcinoma (ACC) is a relatively uncommon malignant epithelial neoplasm characterized by the arrangement of angulated, small basophilic basaloid nuclei in a mixture of tubular, cribriform, and solid growth patterns. Low-grade and intermediate-grade ACCs may have a deceptively benign microscopic appearance yet feature local recurrence and metastatic spread. High-grade ACCs are characterized by a solid growth pattern, which may be anaplastic and feature a desmoplastic stromal response. [1] [2] [3] [4] Approximately 55% to 60% of ACCs originate in the head and neck region, including salivary glands, oropharynx, nasopharynx, and paranasal sinuses, and is the third common malignancy of salivary glands. [1] [2] [3] [4] Twenty percent of ACCs originate from the mid respiratory tract, 10% to 15% develop in the female breast, and the remaining small group of ACCs occur in a wide variety of sites predominantly localized to exocrine glands. [1] [2] [3] [4] When first diagnosed, ACC is predominantly a surgical disease, and wide local excision can be curative in a significant number of patients. [1] [2] [3] [4] In general, the early prognosis of ACC is excellent, with approximately 90% of patients surviving for 5 years. However, owing to its propensity to invade the perineural space, either complete surgical resection may not be possible or indolent cases of ACC can transform into aggressive tumors with late local and systemic relapses, which significantly lower the 10-year survival rate to 40%. 5 When ACC relapses or metastasizes, the disease is generally relentless but progresses at a significantly slower pace than most epithelial malignancies reflecting the generally slow growth rate of the tumor cells themselves. 5 Thus, the prevalence of ACC is significantly higher than the incidence, with 1.49/100,000 people living with the disease in the United States in 2006. 6 The lack of efficacy of cytotoxic treatment for systemic ACC has prompted a significant emerging interest in the search for potential new targets of therapy for the disease. [7] [8] [9] [10] In the following study, we evaluated a series of 28 ACC cases with a sensitive and specific targeted next-generation sequencing (NGS)-based diagnostic assay to assess whether actionable genomic alterations (GAs) could be detected in relapsed and refractory ACC cases that would not be identified in the current diagnostic regimen for this disease.
METHODS
Targeted NGS-based genomic profiling was performed on hybridization-captured, adaptor ligation-based libraries using DNA extracted from 4 formalin-fixed paraffin-embedded sections cut at 10 mm thickness from 28 advanced-stage ACCs that had relapsed after primary surgery in a Clinical Laboratory Improvement Amendments-certified lab (Foundation Medicine). The pathologic diagnosis of each case was confirmed on routine hematoxylin and eosin-stained slides, and tumors were graded according to established criteria 11 ; all samples forwarded for DNA extraction contained a minimum of 20% DNA derived from tumor cells. Samples used for sequencing were obtained from 9 (32%) primary salivary gland tumors, 6 (21%) primary oral cavity tumors, 2 (7%) primary orbital masses, 3 (11%) primary head and neck tumors spread into the bone and soft tissue, 1 (4%) laryngeal primary tumor, and 7 (25%) metastatic tumors including 5 (18%) lung metastases and 1 metastasis (4%) each to the liver and brain. DNA sequencing was performed using a bait set of 3320 exons of 182 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer (1.14 million total bps) and an indexed, adaptor ligated, hybridization-capture system (Agilent SureSelect custom kit). Patient samples were fully sequenced using 49 bp paired reads on the Illumina HiSeq 2000 to at an average depth of 776 Â and evaluated for genomic alterations including base substitutions, insertions, deletions, copy number alterations (amplifications and homozygous deletions), and select gene fusions/rearrangements as previously described. 12 The bioinformatics processes used in this study included Bayesian algorithms to detect base substitutions, local assembly algorithms to detect short insertions and deletions, a comparison with process-matched normal control samples to detect gene copy number alterations and an analysis of chimeric read pairs to identify gene fusions. Actionable GAs were defined as being linked to commercially available targeted therapies on the market or to targeted therapies being tested in registered clinical trials (local site permissions to use clinical samples were used for this study).
RESULTS
Thirteen male (46%) and 15 female (54%) ACC patients, with a mean age of 58.5 years, were included in this study (Supplementary Fig. 1 ). Actionable GAs included truncation of NOTCH1 (3 cases 11%), homozygous deletion of CDKN2A/B (2 cases; 7%), and MDM2 and PDGFRA amplification (each in 2 cases; 7%). Other actionable GAs identified in a single case included mutation in AKT1, BAP1, EGFR, and PIK3CA, homozygous deletion of FBXW7, and amplification of FGFR1, KDR, KIT, and MCL1. The most common nonactionable GAs were identified in KD6MA (5 cases; 18%), ARID1A (4 cases; 14%), RUNX1 (2 cases; 7%), and MYC (2 cases; 7%).
An example of a case from this study that highlights the identification of actionable GAs in ACC includes case 23, an ACC in the parotid of a 46-year-old male patient with extensive perineural space invasion, involvement of surgical margins, and systemic relapses over the ensuing 5 years; the original primary tumor was submitted for NGS analysis and featured amplifications of the CDK4, FGFR1, MYC, IGF1R, and MDM2 genes as well as an E545K mutation in PIK3CA (Fig. 2) . 
DISCUSSION
The frequency of total GAs and potentially actionable GAs in ACC identified in this study is significantly below that seen in more common solid tumors such as breast, colorectal, and non-small cell lung cancers. 13 This lower frequency of discovery of potentially actionable GAs in ACC at 42.8% compared with the 76.4% for a large 2221 overall cohort of solid tumors may reflect the slow tumor cell growth rate, lack of aneuploidy, gene fusion association, and relative DNA stability that is characteristic of ACC. 9, [14] [15] [16] Nonetheless, potential targets of therapy were identified in a number of cases that would not have been identified in the standard diagnostic evaluation of relapsed and metastatic ACCs.
Among the potentially actionable GAs in an ACC is the EGFR mutation in case 17. 17, 18 The EGFR V769M variant in this tumor is an uncommon point mutation within the tyrosine kinase domain that has not been well characterized. EGFR mutations are rarely encountered in ACC, with only 3 (4%) of 83 ACCs of the salivary gland and 0 of 24 ACCs of the upper aerodigestive tract, lung, or breast cancer positive for EGFR mutations (COSMIC, Oct 2012). CDKN2A/B loss was also identified in case 17 and in 7% of the ACCs in the current study, which is comparable to the 10% rate previously reported. 19, 20 Although some studies have shown overexpression of p16 by immunohistochemistry in ACC, 21, 22 others have reported p16 expression loss due to hypermethylation of the p16 gene promoter. [23] [24] [25] Tumors with CDKN2A/B loss may be sensitive to Cdk4/6 inhibitors, and clinical trials of these agents are currently underway. In addition, amplifications of the MDM2 and PDGFRA were identified in 7% of ACCs in this study. MDM2 expression has been linked to ACC tumorigenesis but not to disease progression. 26 MDM2 antagonists have been used in various clinical trials for treatment of multiple tumor types. 27 PDGFRA gain, although not highlevel amplification, has been reported in ACC, but the clinical significance of this finding is unknown. 19 Amplifications of the FGF1R, IGF1R, KIT, and KDR genes were each identified in 4% of ACCs studied and may also guide patients to clinical trials targeting these alterations.
The MYB-NFIB fusion has become the signature chromosomal characteristic of ACC and is found in the majority of ACCs including salivary gland, the head and neck region, respiratory tract, breast, and other primary sites. [28] [29] [30] [31] This alteration is a recurrent reciprocal translocation of t(6;9)(q22-23;p23-24) resulting in fusion gene partners comprising MYB gene and the transcription factor NFIB. Studies have found MYB overexpression in the myoepithelial cells of ACC. 30 The MYB and NFIB genes, although involved in a fusion that is a defining biomarker for a significant number of ACC cases from all primary sites, are currently not targetable GAs by any agents on the market or in clinical development. 8, 28 For this reason, the targeted NGS-based genomic profiling assay used in this study did not include these genes. Recently, 2 whole-exome genomic profiling studies of ACC have been published. One study identified chromatin deregulation in B50% of ACCs (and alterations in ATM, CDKN2A, CYLD, NOTCH1/2, PIK3CA, SF3B1, SPEN, SUFU, and TSC1). 32 Interestingly, that study also reported activating mutations in FGFR2, whereas the current study identified amplification of FGFR1. The second study also reported alterations in chromatin remodeling genes including CREBBP, KDM6A, and SMARCA2, which is similar to the alterations in the chromatin modeling genes ARID1A and KDM6A identified in the current study. 33 This second study also reported a series of mutations in the FGF-IGF-PI3K pathway as seen in the first study and in this report. 8 In summary, targeted NGS-based genomic profiling of relapsed ACC indicates that, although ACC appears to have significantly lower frequencies of GAs than the more common adenocarcinomas of the lung, breast, prostate, and colon, a subset of cases may harbor actionable alterations that can potentially inform on targeted treatment decisions. With an initially indolent clinical course that later transforms into progressive disease, there remains a major unmet clinical need to discover new targets of therapy of ACC that might improve the clinical outcome for patients with currently incurable locally advanced and metastatic disease.
